Post-translational modification by ubiquitin (Ub) regulates many cellular processes. Deregulation of ubiquitination is often associated with disease, including cancer. A key interest of the Ubiquitin Signalling group is to understand the regulation and mechanistic function of the Ub pathway.
Ubiquitin ligases (E3s) catalyse the final step of Ub transfer from the E2~ubiquitin intermediate to the protein target. Recruiting the ubiquitin-charged E2 at a RING-binding domain, MDM2 is an E3 ligase that plays a crucial role in regulating cancer. MDM2 modulates the activity of p53 tumour suppressor protein by inhibiting its transcriptional activity and targeting it for protein degradation. Despite promoting apoptosis and cell cycle arrest, drugs that prevent MDM2 and p53 binding have proven to be highly toxic in the treatment of cancer.
Our recent work demonstrated that the inhibition of MDM2 ubiquitin ligase activity – without affecting the binding of MDM2 and p53 - stabilises p53 but can still limit p53 activity under unstressed condition (Nomura et al. Nature Structural & Molecular Biology 2017). This suggests that targeting the RING domain is a promising strategy in altering the p53-MDM2 axis for cancer therapy.
We have now identified molecules that could modulate the function of the RING domain. The successful PhD candidate will apply structural, biochemical and cell biology to characterise the binding mode and to elucidate the mechanism of inhibiting RING E3s in cancer.
The Cancer Research UK Beatson Institute in Glasgow is one of the world-leading centres for cancer research. The Institute provides an outstanding research environment, underpinned by state-of-the-art core services and advanced technologies with special emphasis on imaging, metabolomics and in vivo models of cancer.
To apply, please click on the ’Visit Website’ button, which will take you to the Beatson Institute website where you should fill in the application form. Please do not email your CV.